Literature DB >> 17716072

Schizotypal personality: neurodevelopmental and psychosocial trajectories.

Adrian Raine1.   

Abstract

Schizotypal personality research holds the promise of critically important insights into the etiology and ultimate prevention of schizophrenia. This article provides a critical overview of diagnostic, developmental, demographic, psychosocial, genetic, neurodevelopmental, psychophysiological, neurochemical, neurocognitive, brain imaging, and prevention-treatment issues pertaining to this personality disorder. It is argued that genetic and early environmental influences act in concert to alter brain structure/function throughout development, resulting in disturbances to basic cognitive and affective processes that give rise to three building blocks of schizotypy-cognitive-perceptual, interpersonal, and disorganized features. Two clinical subtypes are hypothesized: (a) neurodevelopmental schizotypy, which has its roots in genetic, prenatal, and early postnatal factors, is relatively stable, has genetic affinity to schizophrenia, and may benefit preferentially from pharmacological intervention, and (b) pseudoschizotypy, which is unrelated to schizophrenia, has its roots in psychosocial adversity, shows greater symptom fluctuations, and may be more responsive to psychosocial intervention.

Entities:  

Mesh:

Year:  2006        PMID: 17716072     DOI: 10.1146/annurev.clinpsy.2.022305.095318

Source DB:  PubMed          Journal:  Annu Rev Clin Psychol        ISSN: 1548-5943            Impact factor:   18.561


  77 in total

1.  Reappraisal of the interplay between psychosis and depression symptoms in the pathogenesis of psychotic syndromes: results from a twenty-year prospective community study.

Authors:  Wulf Rössler; Jules Angst; Alex Gamma; Helene Haker; Niklaus Stulz; Kathleen R Merikangas; Vladeta Ajdacic-Gross
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-07-13       Impact factor: 5.270

2.  Auditory steady state response in the schizophrenia, first-degree relatives, and schizotypal personality disorder.

Authors:  Olga Rass; Jennifer K Forsyth; Giri P Krishnan; William P Hetrick; Mallory J Klaunig; Alan Breier; Brian F O'Donnell; Colleen A Brenner
Journal:  Schizophr Res       Date:  2012-01-28       Impact factor: 4.939

Review 3.  Emotion processing in persons at risk for schizophrenia.

Authors:  Laura K Phillips; Larry J Seidman
Journal:  Schizophr Bull       Date:  2008-07-21       Impact factor: 9.306

4.  Duration of early maternal separation and prediction of schizotypal symptoms from early adolescence to midlife.

Authors:  Deidre M Anglin; Patricia R Cohen; Henian Chen
Journal:  Schizophr Res       Date:  2008-04-14       Impact factor: 4.939

5.  Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Glen P Davis; Michael T Compton; Shuai Wang; Frances R Levin; Carlos Blanco
Journal:  Schizophr Res       Date:  2013-11-05       Impact factor: 4.939

6.  Personality and psychopathology.

Authors:  Thomas A Widiger
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

7.  Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Authors:  Berker Duman; Nilay Sedes; Bora Baskak
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

Review 8.  Affective traits in schizophrenia and schizotypy.

Authors:  William P Horan; Jack J Blanchard; Lee Anna Clark; Michael F Green
Journal:  Schizophr Bull       Date:  2008-07-29       Impact factor: 9.306

9.  'At-risk' for psychosis research: where are we heading?

Authors:  A Lin; B Nelson; A R Yung
Journal:  Epidemiol Psychiatr Sci       Date:  2012-07-30       Impact factor: 6.892

10.  Pituitary volume in schizophrenia spectrum disorders.

Authors:  F Romo-Nava; W S Hoogenboom; P E Pelavin; J L Alvarado; L H Bobrow; F P Macmaster; M Keshavan; R W McCarley; M E Shenton
Journal:  Schizophr Res       Date:  2013-03-19       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.